Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Set For Expansion With Production of Intermediate For New Vertex Hepatitis Drug

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Although WuXi PharmaTech's planned merger with Charles River Labs was abandoned at the last moment in mid-2010 due to shareholder resistance to the union, the Shanghai-based contract research organization is on track to post solid earnings this year and next, according to a prominent analyst who closely follows China's healthcare sector
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC073826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel